52-Week Performance Chart

Powered by FactSet Research Systems Inc

Capital Raising Events

More
DR Price Date DR Price (USD) US/Non-US/Total DRS US/Non-US/Total DR Capital Raised
Oct 20, 2017 5.00 3,480,000
0
3,480,000
17,400,000
0
17,400,000

Data provided by Thomson Reuters

Institutional Ownership

TOP INSTITUTIONAL HOLDERS POSITION
Palo Alto Investors LP 146,024
Omnia Family Wealth LLC 87,628
Cerity Partners LLC 23,643
TOP MUTUAL FUND HOLDERS POSITION
RiverNorth Capital & Income Fund 1,103
RiverNorth Opportunities Fund Inc. 508
LUX IM - Global Medtech 14

Data provided by FactSet Research Systems Inc.

DR Details

DR Symbol AKTX
CUSIP 00972G207
DR Venue NASDAQ Stock Market
DR ISIN US00972G2075
Ratio DR:ORD 1:2000
Local Exchange Not Traded
Underlying ISIN GB00B807GC03
Country United Kingdom
Effective Date Dec 07, 2012
Depositary DB (Sponsored)
Industry Pharma. & Biotech.
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Apr.25 1.44 621,048 29,574
Mar.25 1.24 687,266 32,727
Feb.25 0.87 565,443 29,760

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE